About NDC-1308 For Inducing Remyelination
A new drug with the potential to induce remyelination, the process for restoring and repairing the myelin sheath in demyelinating diseases including multiple sclerosis (MS), transverse myelitis and osmotic demyelination syndrome.
How the Body Makes Myelin
Oligodendrogenesis:
the body’s natural process for forming mature, myelinating oligodendrocytes leading to myelin sheaths. The process start from oligodendrocyte progenitor cells (OPCs) that are located throughout the central nervous system (CNS).
NDC-1308 Induces the Body’s Natural System for Oligodendrogenisis
NDC-1308 is currently in late preclinical development, it is designed to address one of the root causes of demyelinating disease by inducing oligodendrocyte progenitor cells (OPCs) – the precursors of oligodendrocytes – to mature into oligodendrocytes, the cells that synthesize and maintain the myelin sheath.
Step 1:
Oligodendrocyte progenitor cells (OPCs) are present but quiescentNDC-1308
Designed to up-regulate key genes to induce remyelinationStep 2:
Gene activated by NDC-1308
Step 3:
Pre-oligodendrocytes become pre-myelinating oligodendrocytesStep 4:
Pre-myelinating oligodendrocytes become myelinating oligodendrocytesA Multiple Target Approach
The unique remyelinating activity of NDC-1308 comes from its ability to significantly up-regulate key genes necessary for OPC differentiation into mature oligodendrocytes.
To learn more go to:
Developing new drugs for diseases with limited or non-existent treatment options.
TO REQUEST MORE INFORMATION GO TO:
www.endece.com/contact
TO REQUEST MORE INFORMATION GO TO:
www.endece.com/contact